MRNA Moderna Inc.

14.32
+0.12  (+1%)
Previous Close 14.2
Open 14.28
Price To Book 3.25
Market Cap 4,711,326,826
Shares 329,003,270
Volume 722,569
Short Ratio
Av. Daily Volume 1,394,583

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 completed.
VEGF-A(AZD8601)
Myocardial ischemia
Phase 1 completed.
mRNA-2416
Solid tumors, lymphoma
Phase 1 updated data ASCO June 1, 2019. 30% ORR (1 CR; 5 PRs).
mRNA-4157 - KEYNOTE-603
Personalized cancer vaccine
Phase 1 completed.
mRNA-1388
Chikungunya vaccine
Phase 1 completed.
mRNA-1851
Influenza vaccine
Phase 1 completed.
mRNA-1440
Influenza vaccine
Phase 1 ongoing.
mRNA-1653
Human Metapneumovirus and Human Parainfluenza Infection (hMPV+PIV3 vaccine)
Phase 1 ongoing.
mRNA-1647
CMV vaccine (Cytomegalovirus Infection)
Development has been paused - May 8, 2019.
mRNA-1777
RSV vaccine
Phase 1/2 trial planned.
mRNA-3704
Methylmalonic Acidemia (MMA)
Phase 1 dosing has commenced - noted January 8, 2019.
mRNA-2752
Solid tumors, lymphoma
Phase 1 initiation of dosing announced February 5, 2019.
mRNA-1944
Chikungunya Virus Infection
Phase 1 data presented at ASCO June 1, 2019.
mRNA-4650
Autologous Cancer